---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-008137"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T14:00:18.963977+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma Q4 2024 revenue $11.6M (+59% YoY); net loss narrows to $0.6M

## Summary
- Record product revenue of $11.6M in Q4 2024, up 59% from Q4 2023; 16th consecutive quarter of sequential growth.
- Net loss improved to $0.6M ($0.02/share) vs $2.3M loss ($0.09/share) in Q4 2023.
- Closed transformational acquisition of Increlex (relaunched Jan 2025) and acquired Galzin; both tracking ahead of expectations.
- Positive pivotal study for ET-600; NDA submission planned April 2025; ET-400 launch inventory ready with PDUFA May 28.
- Cash balance $14.9M at Dec 31, 2024; company expects sequential revenue growth to continue.

## SEC filing metadata
- accession: 0001437749-25-008137
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774925008137/0001437749-25-008137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774925008137/eton20250305_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-008137
- JSON: https://secwatch.observer/filing/0001437749-25-008137.json
- Plain text: https://secwatch.observer/filing/0001437749-25-008137.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.